Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best pharma stocks to invest in. Cantor Fitzgerald analyst Carter Gould maintained a Buy rating on Gilead Sciences, Inc. (NASDAQ:GILD) on December 7, setting a price target of $135.
The same day, Kite, a Gilead Sciences, Inc. company, released a new analysis showing that second-line Yescarta therapy offers consistent benefits in patients living with relapsed/refractory large B-cell lymphoma, even among those ineligible for the previous standard of care, high-dose chemotherapy after an autologous stem cell transplant (ASCT).
Management reported that the benefits were noted irrespective of eligibility for previous standard of care of high-dose chemotherapy and stem cell transplant for second-line treatment. Professor Roch Houot, Head of Haematology Department, University Hospital of Rennes, France, and coordinator of the ALYCANTE study, stated the following about the development:
“Patients with large B-cell lymphoma who are ineligible for stem cell transplants face limited treatment options and poor outcomes due to age, co-morbidities and other factors. This analysis reinforces that Yescarta should be considered earlier in a patient’s treatment paradigm given its curative potential as a one-time treatment and further establishes CAR T as the new standard of care for second-line treatment of large B-cell lymphoma.”
Gilead Sciences, Inc. is a biopharmaceutical company that advances medicines to prevent and treat serious diseases such as cancer, immunodeficiency virus (HIV), viral hepatitis, and COVID-19. Its portfolio of drugs focuses on medical areas with unmet needs and includes AmBisome, Atripla, Biktarvy, Cayston, Complera, and others. Gilead Sciences, Inc. operates in over 35 countries.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
This article is originally published at Insider Monkey.
